A study of pharmacokinetics and safety on repeated application of flurbiprofen-containing patch (Tape) (LC1702) in healthy adult males.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031240583

Enrollment

Registered

2024-12-26

Start date

2025-01-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain relief and anti-inflammation

Interventions

Repeated transdermal application of LC1702 and ADF.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: (1) Age: 18 to 40 years old (at the time of obtaining consent) (2) Persons whose BMI [Body Mass Index: weight (kg) / height (mm)^2] is 18.5 kg/m^2 or more and less than 25 kg/m^2 (numbers are not rounded) (3) Persons who can quit smoking during their stay

Exclusion criteria

Exclusion criteria: (1) Persons with hypersensitivity or idiosyncrasy to drugs, etc. (2) Persons with a history of bronchial asthma. (3) Persons with diseases of the gastrointestinal tract, heart, liver, kidneys, etc. that affect drug metabolism and excretion. (4) Persons with skin wounds at the application site, and those who have skin symptoms such as eczema, contact dermatitis, psoriasis, seborrheic dermatitis, dyschromatosis, and excessive sunburn at the application site.

Design outcomes

Primary

Measure	Time frame
Drug concentration in plasma	—

Contacts

Public ContactNoriko Kurihara

Tokyo Research Center of Clinical Pharmacology Co., Ltd.

n-kurihara@trcp.co.jp+81-3-5366-3006

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026